Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 20;17(20):7630.
doi: 10.3390/ijerph17207630.

Managing Cystic Fibrosis in Polish Healthcare

Marta Rachel  1   2 , Stanisław Topolewicz  3 , Andrzej Śliwczyński  4 , Sabina Galiniak  1
Affiliations

Managing Cystic Fibrosis in Polish Healthcare

Marta Rachel et al. Int J Environ Res Public Health. .

Abstract

The quality and length of life of patients with cystic fibrosis (CF) are determined by a number of factors including the quality of healthcare received by patients, as well as access to drug programs dedicated to this particular disease. The purpose of this paper is to present an overview of changes in the average life expectancy and mortality rate of the CF population in Poland between 2000 and 2018. Furthermore, we would like to evaluate access to healthcare services, including the drug program, guaranteed by public healthcare system, and funded by National Health Fund (NHF). The average life expectancy of patients with CF increased in the period in question from ca. 14.5 ± 7.6-24.5 ± 8.9 years (mean ± SD, p = 0.0001). We have observed a drop in the number of deaths in paediatric age during that period. Despite the increase in life expectancy, the use of health resources in patients with CF, especially the drug program, is dramatically low. Considering the fact that in Poland there was no active countrywide CF registry, now it is possible to estimate the frequency of use of CF healthcare services in various provinces exclusively on the basis of database maintained by the Polish NHF.

Keywords: cystic fibrosis; deaths; drug program; hospital treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Average life span of cystic fibrosis (CF) patients in the 2000–2018 period.
Figure 2
Figure 2
The number of deaths of patients with CF in the 2000–2018 period.
Figure 3
Figure 3
Percentage of deaths of paediatric CF patients in the 2000–2018 period.
Figure 4
Figure 4
Number of deaths depending on the patient’s age.
Figure 5
Figure 5
Percentage of patients diagnosed with E84 who benefitted from various services in 2018.
Figure 6
Figure 6
Distribution of services financed by NHF according to patients’ gender and age for all types of services and hospital care in 2018.
Figure 7
Figure 7
Distribution of hospital services according to the patient age and gender in 2018.
Figure 8
Figure 8
Distribution of drug program services according to the patients’ age and gender in 2017.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sands D., Pogorzelski A., Skoczylas-Ligocka A. Epidemiologia i Organizacja Opieki Medycznej Nad Chorymi na Mukowiscydozę w Polsce. In: Sands D., editor. Mukowiscydoza Choroba Wieloukładowa. Termedia; Poznań, Poland: 2018. pp. 15–24.
    1. Farrel P.M. Case report: The prevalence of cystic fibrosis in the European Union. J. Cyst. Fibros. 2008;7:450–453. doi: 10.1016/j.jcf.2008.03.007. - DOI - PubMed
    1. Singh M., Rebordosa C., Bernholz J., Sharma N. Epidemiology and genetics of cystic fibrosis in Asia: In preparation for the next-genaration treatments. Respirology. 2015;20:1172–1181. doi: 10.1111/resp.12656. - DOI - PubMed
    1. Mirtajani S.B., Farnia P., Hassanzad M., Ghanavi J., Velayati A.A. Geographical distribution of cystic fibrosis; The past 70 Years of data analysis. Biomed. Biotechnol. Res. J. 2017;1:105–112.
    1. Bodnar R., Kadar L., Holics K., Ujhelyi R., Kovacs L., Bolbas K., Szekely G., Gyurkovits K., Solyom E., Meszaros A. Factors influencing quality of life and disease severity in Hungarian children and young adults with cystic fibrosis. Ital. J. Pediatr. 2014;40:50. doi: 10.1186/1824-7288-40-50. - DOI - PMC - PubMed